Evaluation of an algorithm ascertaining cases of osteonecrosis of the jaw in the Swedish national patient register

Clinical Epidemiology

Volumn 5, Issue 1, 2013, Pages 1-7

  Bergdahl, Johan ^a   Jarnbring, Fredrik ^b   Ehrenstein, Vera ^c   Gammelager, Henrik ^c   Granath, Fredrik ^a   Kieler, Helle ^a   Svensson, Madeleine ^a   Tell, Grethe S ^d   Lagerros, Ylva Trolle ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Bisphosphonate associated osteonecrosis of the jaw; Epidemiology; Methods; ONJ; Registries; Validation

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTISONE; CYTOSTATIC AGENT; PARATHYROID HORMONE[1-34]; PROTON PUMP INHIBITOR;

ADULT; AGED; ALGORITHM; DENTOALVEOLAR SURGERY; FEMALE; HUMAN; ICD-10; JAW OSTEONECROSIS; MANDIBLE; MAXILLA; MEDICAL RECORD; MEDICAL RECORD REVIEW; ORAL SURGERY; POSTMENOPAUSE; PREDICTIVE VALUE; REGISTER; REVIEW; SENSITIVITY ANALYSIS; SURGICAL WARD; SWEDEN;

EID: 84872516137     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S37664     Document Type: Review

References (27)

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115-1117.
2. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg. 2005;63(5):682-689.
3. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 2009;122(Suppl 2): S33-S45.
4. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; for American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws 2009 update. J Oral Maxillofac Surg. 2009;67(Suppl 5):2-12.
5. Khosla S, Burr D, Cauley J, et al; for American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479-1491.
6. Van Poznak C. Making a case for defining osteonecrosis of the jaw. J Dent Res. 2011;90(4):399-401.
7. Saad F, Brown JE, Van Poznak C, et al.Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341-1347.
8. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-1132.
9. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-5139.
10. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-822.
11. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010;136(8):1117-1124.
12. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. 2006;7(6):508-514.
13. Ruggiero SL, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med. 2009;60:85-96.
14. Fleisher KE, Welch G, Kottal S, Craig RG, Saxena D, Glickman RS. Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers. Oral Surg Oral Pathol Oral Radiol Endod. 2010;110(4):509-516.
15. Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci. 2011;1218:47-54.
16. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27(32):5356-5362.
17. Landesberg R, Woo V, Cremers S, et al. Potential pathophysiological mecha nisms in osteonecrosis of the jaw. Ann N Y Acad Sci. 2011;1218: 62-79.
18. Rydh H. Patientregistret. [National Patient Register]. [webpage on the Internet]. Stockholm, Sweden: National Board of Health and Welfare. Available from: http://www.socialstyrelsen.se/register/halsodataregister/patientregistret. Accessed March 27, 2012. Swedish.
19. Rydh H. För uppgiftslämnare till patientregistret. [For information providers of the National patient Register]. [webpage on the Internet]. Stockholm, Sweden: National Board of Health and Welfare. Available from: http://www.socialstyrelsen.se/register/halsodataregister/patien-tregistret/foruppgiftslamnarepatientregistret. Accessed March 27, 2012. Swedish.
20. Rydh H. Variabelförteckning. [Patientregistret. Record of variables-the National Patient Register]. [webpage on the Internet]. Stockholm, Sweden: National Board of Health and Welfare. Available from: http://www.socialstyrelsen.se/register/halsodataregister/patientregistret/variabelforteckning. Accessed March 27, 2012. Swedish.
21. Leimanis A. Läkemedelsregistret. [Prescribed Drug Register]. [webpage on the Internet]. Stockholm, Sweden: National Board of Health and Welfare. Available from: http://www.socialstyrelsen.se/register/halso-dataregister/lakemedelsregistret. Accessed March 27, 2012. Swedish.
22. Otto S, Schreyer C, Hafner S, et al. Bisphosphonate-related osteonecrosis of the jaws characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg. 2012;40(4):303-309.
23. Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol. 2011;8(2):90-96.
24. Jung TI, Hoffmann F, Glaeske G, Felsenberg D. Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy. J Cancer Res Clin Oncol. 2010;136(3):363-370.
25. Patel S, Choyee S, Uyanne J, et al. Non-exposed bisphosphonate related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. Oral Dis. 2012;18(7): 625-632.
26. Yamashita J, McCauley LK, Van Poznak C. Updates on osteonecrosis of the jaw. Curr Opin Support Palliat Care. 2010;4(3):200-206.
27. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.